GS-100 ha'e peteĩ vector AAV9 recombinante omohendáva gen NGLY1 yvypórape. Ohupyty orphan drug designación US Food and Drug Administration ha European Medicine Agency (EMA) guive. Ko terapia ohupyty avei FDA's rare paediatric disease designación 2021 ha fast track designación ary ohasava'ekuépe.
#SCIENCE #Guarani #CU
Read more at Clinical Trials Arena